Mylan Launches Generic Version of Aciphex® Tablets
PITTSBURGH, Nov. 11, 2013
PITTSBURGH, Nov. 11, 2013 /PRNewswire/ --Mylan Inc. (Nasdaq: MYL) today
announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has
launched Rabeprazole Sodium Delayed-release Tablets, 20 mg. Rabeprazole Sodium
Delayed-release Tablets are the generic version of Eisai Corporation's
Aciphex^® Tablets, and are indicated for short-term treatment in the healing
and symptomatic relief of erosive or ulcerative gastroesophageal reflux
disease, and for short-term treatment in the healing and symptomatic relief of
duodenal ulcers. Mylan received final approval from the U.S. Food and Drug
Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this
Aciphex Tablets, 20 mg, had U.S. sales of approximately $830.1 million for the
12 months ending Sept. 30, 2013, according to IMS Health.
Currently, Mylan has 179 ANDAs pending FDA approval representing $90.5 billion
in annual sales, according to IMS Health. Forty of these pending ANDAs are
potential first-to-file opportunities, representing $24.1 billion in annual
brand sales, for the 12 months ending June 30, 2013, according to IMS Health.
Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of more than 1,200 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com
SOURCE Mylan Inc.
Contact: Nina Devlin (Media), 724.514.1968; Kris King (Investors),
Press spacebar to pause and continue. Press esc to stop.